Open Access

The effects of Antidepressant Therapy on Health-Related Quality of Life in Patients with a Chronic Obstructive Pulmonary Disease and Depressive Symptoms

Ivana Jelic

Ivana Jelic

University of Kragujevac, Faculty of Medical SciencesKragujevac, Serbia
Search for this author on
Sciendo|Google Scholar
Jelic, Ivana
, 
Marko Folic

Marko Folic

  • University of Kragujevac, Faculty of Medical SciencesKragujevac, Serbia
  • Clinical Pharmacology Department, University Clinical Centre KragujevacKragujevac, Serbia
Search for this author on
Sciendo|Google Scholar
Folic, Marko
, 
Filip Mihajlovic

Filip Mihajlovic

University of Kragujevac, Faculty of Medical SciencesKragujevac, Serbia
Search for this author on
Sciendo|Google Scholar
Mihajlovic, Filip
, 
Slobodan Jankovic

Slobodan Jankovic

  • University of Kragujevac, Faculty of Medical SciencesKragujevac, Serbia
  • Clinical Pharmacology Department, University Clinical Centre KragujevacKragujevac, Serbia
Search for this author on
Sciendo|Google Scholar
Jankovic, Slobodan
 and 
Goran Mihajlovic

Goran Mihajlovic

  • University of Kragujevac, Faculty of Medical SciencesKragujevac, Serbia
  • Psychiatry Clinic, University Clinical Centre KragujevacKragujevac, Serbia
Search for this author on
Sciendo|Google Scholar
Mihajlovic, Goran
  
Jan 17, 2022
The effects of Antidepressant Therapy on Health-Related Quality of Life in Patients with a Chronic Obstructive Pulmonary Disease and Depressive Symptoms's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Original Scientific Article
Published Online: Jan 17, 2022
Page range: 243 - 248
Received: Nov 18, 2021
Accepted: Dec 19, 2021
DOI: https://doi.org/10.2478/sjecr-2021-0068
Keywords
© 2024 Ivana Jelic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Characteristics of the study (n=87) group, and main outcomes_

Variable Values
Age (years) 48.84±7.43
Gender (male) 30 (34.5%)
FEV1 (%) 74.79±15.07
mMRC Stage 1 34 (39.1%)
Stage 2 43 (49.4%)
Stage 3 10 (11.5%)
HAM-D scale score before SSRIs therapy 15.79±4.43 Related samples Wilcoxon signed rank test p<0.001
HAM-D scale score after 8 weeks of SSRIs therapy 10.02±3.97
Q-LES-Q-SF score before AD 32.43±5.51 Related samples Wilcoxon signed rank test p<0.001
Q-LES-Q-SF score after AD 46.65±4.79
Difference in Q-LES-Q-SF score (after – before) 14.20 ± 2.02

Significant predictor of difference between values of the Q-LES-Q-SF score after and before the treatment with SSRIs_

Predictor Adjusted R2 F B t p 95,0% Confidence Interval for B
Lower Bound Upper Bound
FEV1 0.051 5.625 (p=0.020) −0.034 −2.372 0.020 −0.062 −0.005
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Clinical Medicine, other
Journal RSS Feed